Kabra Drugs has informed that as on the 35th Annual General Meeting of the Company held on Monday, 30th September 2024 at 10.00 am at registered office of the company and meeting ended at 10.30 am, transacted the following business - Approved the financial statement for the year ended 31st March 2024, together with Auditors' Report and Directors' Report; Bangalore Venkata Krishnappa Ananthkumar (Din No. 08644948) was re-appointed as Director of the company in 35th Annual General Meeting held on 30th September, 2024; appointed PPN And Company Chartered Accountants, (FRN:013623S) as Statutory Auditors and fixed their Remuneration for an initial term of 5 years; approved to shift registered office of the Company from 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh - 452011. to Kabra Drugs Ltd, No: 3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai - 600 033; Approved the re-appointment of B V Anatha Kumar (Din:08644948) as the WholeTime Director of the Company for a term of 2 years; Approved the regularization of N. Aravind (Din: 01895602) as Managing Director on The Board of the Company; pproved the change in designation of Kuniamuthur Nanjappan Anand (Din: 03230186) as the Executive Director of the Company. The Company has received a request from the below-mentioned shareholder for issuance of Duplicate Share Certificates consequent to loss of original Share Certificates. The details of lost certificates are enclosed.
The above information is a part of company’s filings submitted to BSE.